BeStock  
Stocks › Biotechnology › ALNY

Alnylam Pharmaceuticals ALNY

US equityMarket cap rank #427Biotechnology
$236.54 −$10.20 (-4.13%)
Market open · Oct 1, 1:20 pm ET · After hours $246.74 0.00%
Open$248.21
Prev close$246.74
Day range$233.53 – $251.71
Volume868.2K
Market cap$31.65B
P/E (TTM)41.2
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$1.29B+66.9% YoY
Operating profit$231.44M+1,528.7% YoY
Net profit$164.49M+327.7% YoY
Diluted EPS$1.21+320.0% YoY
Free cash flow$292.04M+152.8% YoY
Operating cash flow$326.72M

Revenue, last 8 quarters

$500.9MSep '24$593.2MDec '24$594.2MMar '25$773.7MJun '25$1.2BSep '25$1.1BDec '25$1.2BMar '26$1.3BJun '26

Net profit, last 8 quarters

$-111.6MSep '24$-83.8MDec '24$-18.3MMar '25$-72.2MJun '25$251.1MSep '25$186.4MDec '25$206.0MMar '26$164.5MJun '26

Diluted EPS by quarter

-0.87Sep '24-0.65Dec '24-0.14Mar '25-0.55Jun '251.84Sep '250.82Dec '251.51Mar '261.21Jun '26

Free cash flow by quarter

$39.5MSep '24$-103.8MDec '24$-129.3MMar '25$115.5MJun '25$338.9MSep '25$140.3MDec '25$48.7MMar '26$292.0MJun '26

Annual revenue

$492.9MFY20$844.3MFY21$1.0BFY22$1.8BFY23$2.2BFY24$3.7BFY25

Profitability & balance sheet

Gross margin79.7%
Operating margin20.8%
Net margin16.1%
Return on equity96.6%
Return on assets15.3%
Return on invested capital42.2%
Current ratio3.05
Liabilities / assets75.6%
Cash & investments$3.31B
Total debt$1.22B
Net cash (debt)$2.09B
Free cash flow / sales17.1%

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $1.29B $1.17B $3.71B $1.10B $1.25B
Total Operating Revenue $1.29B $1.17B $3.71B $1.10B $1.25B
Cost of Revenue $298.45M $211.12M $681.87M $267.72M $200.15M
Gross Profit $992.50M $956.05M $3.03B $829.31M $1.05B
Operating Expense $761.06M $687.42M $2.53B $697.59M $680.89M
Selling and Admin Expenses $347.92M $322.55M $1.21B $325.37M $322.08M
-General & Admin Expense $347.92M $322.55M $1.21B $325.37M $322.08M
Research & Development $413.13M $364.87M $1.32B $372.22M $358.81M
Operating Profit $231.44M $268.64M $501.58M $131.72M $367.98M
Net Non-Operating Interest Income (Expense) -$53.91M -$42.69M -$141.16M -$102.71M -$15.72M
Non-Operating Interest Income $28.14M $26.60M $111.47M $26.63M $28.68M
Non-Operating Interest Expense $82.05M $69.29M $252.63M $129.34M $44.40M
Other Income (Expense) $273,000.00 -$4.30M -$37.27M $132.13M -$113.30M
Other Non-Operating Income (Expenses) $273,000.00 -$4.30M $7.51M -$3.36M -$9.49M
Pretax Profit $177.81M $221.65M $323.15M $161.14M $238.97M
Tax $13.31M $15.66M $9.41M -$25.28M -$12.12M
Net Profit $164.49M $205.99M $313.75M $186.42M $251.08M
Profit from Continuing Operations $164.49M $205.99M $313.75M $186.42M $251.08M
Net Income to Parent Company $164.49M $205.99M $313.75M $186.42M $251.08M
Net Income to Common Stockholders $164.49M $205.99M $313.75M $186.42M $251.08M
Basic EPS $1.23 $1.55 $2.39 $0.84 $1.91
Diluted EPS $1.21 $1.51 $2.33 $0.82 $1.84
Gain on Sale of Security – – -$2.31M $138.81M -$64.66M
Special Income (Charges) – – -$42.47M -$3.33M -$39.15M
-Less:Other Special Charges – – $42.47M $3.33M $39.15M

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $5.56B $5.13B $4.97B $4.97B $4.85B
Total Current Assets $4.62B $4.22B $4.05B $4.05B $3.95B
Cash and Cash Equivalents & Short-Term Investments $3.31B $3.01B $2.91B $2.91B $2.72B
-Cash and Cash Equivalents $1.71B $1.71B $1.66B $1.66B $1.49B
-Short Term Investments $1.60B $1.30B $1.25B $1.25B $1.23B
Receivables $912.74M $883.96M $777.57M $777.57M $964.77M
-Accounts Receivable $912.74M $883.96M $777.57M $777.57M $964.77M
Inventory $97.11M $84.03M $82.72M $82.72M $75.38M
Other Current Assets $302.18M $242.10M $281.89M $281.89M $188.04M
Total Non-Current Assets $938.60M $910.24M $915.67M $915.67M $898.85M
Net PPE $737.50M $707.56M $708.06M $708.06M $693.14M
-Gross PPE $737.50M $707.56M $1.03B $1.03B $693.14M
Non-Current Deferred Assets $113.79M $116.96M $125.98M $125.98M $98.56M
Other Non-Current Assets $87.30M $85.72M $81.63M $81.63M $107.15M
Total Liabilities $4.20B $4.05B $4.18B $4.18B $4.62B
Total Current Liabilities $1.51B $1.35B $1.47B $1.47B $1.56B
Payables $108.02M $126.63M $115.72M $115.72M $117.59M
-Accounts Payable $108.02M $126.63M $115.72M $115.72M $117.59M
Current Accrued Expenses $1.10B $946.49M $823.00M $823.00M $1.15B
Short-Term Debt and Capital Lease Obligation $45.93M $45.66M $45.52M $45.52M $44.76M
-Current Capital Lease Obligation $45.93M $45.66M $45.52M $45.52M $44.76M
Current Deferred Liabilities $4.01M $3.21M $4.85M $4.85M $2.54M
Other Current Liabilities $258.57M $227.49M $220.07M $220.07M $236.94M
Total Non-Current Liabilities $2.69B $2.70B $2.71B $2.71B $3.06B
Long Term Debt and Capital Lease Obligation $1.22B $1.23B $1.23B $1.23B $1.26B
-Long Term Debt $1.01B $1.01B $1.01B $1.01B $1.04B
-Long Term Capital Lease Obligation $210.50M $218.03M $225.09M $225.09M $223.42M
Other Non-Current Liabilities $1.47B $1.48B $1.48B $1.48B $1.36B
Total Equity $1.35B $1.08B $789.18M $789.18M $233.89M
Stockholders' Equity $1.35B $1.08B $789.18M $789.18M $233.89M
Capital Stock $1.34M $1.33M $1.32M $1.32M $1.32M
-Common Stock $1.34M $1.33M $1.32M $1.32M $1.32M
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $7.72B $7.60B $7.51B $7.51B $7.41B
Retained Earnings -$6.33B -$6.50B -$6.70B -$6.70B -$7.16B
Gains/Losses Not Affecting Retained Earnings -$32.14M -$24.89M -$20.10M -$20.10M -$21.78M
-Accumulated Depreciation – – -$322.70M -$322.70M –
Derivative Product Liabilities – – $0.00 $0.00 $439.66M

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow $326.72M $70.50M $524.08M $163.56M $351.03M
Net cash flow from continuing operations $326.72M $70.50M $524.08M $163.56M $351.03M
Net Income from Continuing Operations $164.49M $205.99M $313.75M $186.42M $217.81M
Depreciation & Depletion & Amortization $13.90M $13.55M $55.66M $13.51M $13.80M
Deferred Tax $2.66M $9.31M -$2.20M -$27.17M $5.60M
Other Non-Cash Items $87.32M $69.23M $251.11M $170.28M $6.39M
Change in Working Capital -$28.27M -$297.73M -$444.78M -$73.15M -$178.74M
-Change in Receivables -$31.60M -$110.42M -$359.96M $184.25M -$399.86M
-Change in Inventory $280,000.00 -$3.32M $8.47M -$13.86M $4.98M
-Change in Prepaid Assets -$59.37M -$6.32M -$117.72M -$70.99M -$20.74M
-Change in Payables and Accrued Expense $61.62M -$176.03M $75.07M -$174.85M $249.43M
-Change In Other Working Capital $802,000.00 -$1.63M -$50.64M $2.31M -$12.54M
Net cash flow from investing -$363.46M -$25.54M $436.33M -$37.17M $501.11M
Net Cash Flow from Continuing Investing Activities -$363.46M -$25.54M $436.33M -$37.17M $501.11M
Net PPE Purchase and Sale -$34.68M -$21.83M -$58.70M -$23.29M -$12.14M
Net Investment Purchase and Sale -$302.88M -$48.43M $497.18M -$13.87M $515.40M
Net Other Investing Changes -$25.90M $44.73M -$2.15M $0.00 –
Financing Cash Flow $36.24M $15.71M -$305.19M $45.32M -$474.27M
Net Cash Flow from Continuing Financing Activities $36.24M $15.71M -$305.19M $45.32M -$474.27M
Proceeds from Stock Option Exercised $33.56M $13.16M $250.03M $41.70M $77.74M
Net Other Financing Charges $2.68M $2.56M -$10.69M $56.55M -$60.41M
Ending Cash Balance $1.71B $1.71B $1.66B $1.66B $1.49B
Net Change in Cash -$496,000.00 $60.68M $655.22M $171.71M $377.87M
Beginning Cash Balance $1.71B $1.66B $968.65M $1.49B $1.12B
Effect of Exchange Rate Changes -$2.45M -$7.06M $34.94M -$5.70M -$927,000.00
Free Cash Flow $292.04M $48.67M $465.38M $140.26M $338.89M
Gain/Loss from Continuing Operations – – $2.31M -$177.96M $177.96M
Net Issuance Payments Of Debt – – -$544.53M -$52.93M –

Discussion

No comments yet — be the first to weigh in on ALNY.

Leave a comment

Scroll to Top